Superworth

Anika Therapeutics price to sales ratio ANIK

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
2.4×
10-year median
4.0×
Against its 10-year history
32nd
percentile: 0 is its lowest day, 100 its highest
10-year range
1.2× to 9.3×
Peer median
1.8×

Anika Therapeutics' price to sales ratio is 2.4× as of Oct 23, 2026.

That is below its ten-year median of 4.0×, lower than on 68% of days in the last ten years.

Over that time it ranged from 1.2× in Apr 2025 to 9.3× in Oct 2019.

The median for 10 medical instruments and supplies stocks of a similar size is 1.8×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.4×1.6×2.4×
20251.3×1.2×1.6×
20241.4×1.4×2.5×
20232.0×1.6×3.1×
20222.8×2.0×3.4×
20213.6×3.6×5.2×
20205.0×3.2×6.6×
20196.7×4.0×9.3×
20184.2×4.0×8.8×
20177.0×6.0×7.9×
20166.8×5.8×8.0×
20156.5×4.8×7.4×
20145.5×5.2×8.6×
20136.6×2.1×6.6×
20122.0×2.0×3.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest Anika Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
ANIKAnika Therapeutics2.4×
INFUInfuSystem1.9×
UTMDUtah Medical Products6.5×
EMBCEmbecta0.4×
PDEXPro DEX2.6×
TCMDTactile Systems Technology1.5×
MDXGMimedx1.6×
MOVMovado1.0×
KEQUKewaunee Scientific0.3×
IRMDIradimed12.7×
STAAStaar Surgical3.3×
Peer median1.8×

Where Anika Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Anika Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.